Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1

Belite Bio, Inc. BLTE.O:

Belite Bio announces submission of new drug application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake designation system for tinlarebant for the treatment of Stargardt disease type 1

Belite Bio, - FDA accepts NDA with priority review for tinlarebant; PDUFA target date Feb. 12, 2027